像Wegovy这样的重量损失的药物 面临保险的削减 使得许多病人难以负担费用 Weight-loss drugs like Wegovy face coverage cuts, leaving many patients struggling to afford them.

患者很难获得像Wegovy和Zepbound这样流行的减重药品, Patients struggle to access popular weight-loss drugs like Wegovy and Zepbound due to inconsistent coverage. 尽管供应有所改善,但许多雇主和承保人正在减少覆盖面,《医疗保险计划》没有覆盖这些肥胖症药物。 Despite improved supplies, many employers and insurers are reducing coverage, and Medicare does not cover these drugs for obesity. 费用高昂,往往每月超过200美元,使许多人无法在没有保险的情况下负担这些费用。 The high cost, often over $200 per month, makes them unaffordable for many without insurance. 很大一部分人口可能从这些治疗中受益,但缺乏一贯的覆盖率使长期使用和有效性复杂化。 A large portion of the population could benefit from these treatments, but the lack of consistent coverage complicates long-term use and effectiveness.